153 related articles for article (PubMed ID: 10792277)
1. Waldenström's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil.
Kyle RA; Greipp PR; Gertz MA; Witzig TE; Lust JA; Lacy MQ; Therneau TM
Br J Haematol; 2000 Mar; 108(4):737-42. PubMed ID: 10792277
[TBL] [Abstract][Full Text] [Related]
2. Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.
Dimopoulos MA; Trotman J; Tedeschi A; Matous JV; Macdonald D; Tam C; Tournilhac O; Ma S; Oriol A; Heffner LT; Shustik C; García-Sanz R; Cornell RF; de Larrea CF; Castillo JJ; Granell M; Kyrtsonis MC; Leblond V; Symeonidis A; Kastritis E; Singh P; Li J; Graef T; Bilotti E; Treon S; Buske C;
Lancet Oncol; 2017 Feb; 18(2):241-250. PubMed ID: 27956157
[TBL] [Abstract][Full Text] [Related]
3. Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study.
Furman RR; Eradat HA; DiRienzo CG; Hofmeister CC; Hayman SR; Leonard JP; Coleman M; Advani R; Chanan-Khan A; Switzky J; Liao QM; Shah D; Jewell RC; Lisby S; Lin TS
Lancet Haematol; 2017 Jan; 4(1):e24-e34. PubMed ID: 27914971
[TBL] [Abstract][Full Text] [Related]
4. Waldenström's macroglobulinaemia: results of a combined oral treatment in 34 newly diagnosed patients.
Petrucci MT; Avvisati G; Tribalto M; Giovangrossi P; Mandelli F
J Intern Med; 1989 Dec; 226(6):443-7. PubMed ID: 2518735
[TBL] [Abstract][Full Text] [Related]
5. Phase III study of chlorambucil versus fludarabine as initial therapy for Waldenstrom's macroglobulinemia and related disorders.
Johnson SA; Owen RG; Oscier DG; Leblond V; Levy V; Jaeger U; Seymour JF
Clin Lymphoma; 2005 Mar; 5(4):294-7. PubMed ID: 15794869
[TBL] [Abstract][Full Text] [Related]
6. Waldenström's macroglobulinaemia treated with cylophosphamide and chlorambucil.
Buckle RM; Jenkins GC; Mills GL
J Clin Pathol; 1966 Jan; 19(1):55-9. PubMed ID: 4955538
[TBL] [Abstract][Full Text] [Related]
7. Alkylating agents for Waldenstrom's macroglobulinaemia.
Yang K; Tan J; Wu T
Cochrane Database Syst Rev; 2009 Jan; (1):CD006719. PubMed ID: 19160296
[TBL] [Abstract][Full Text] [Related]
8. Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases.
García-Sanz R; Montoto S; Torrequebrada A; de Coca AG; Petit J; Sureda A; Rodríguez-García JA; Massó P; Pérez-Aliaga A; Monteagudo MD; Navarro I; Moreno G; Toledo C; Alonso A; Besses C; Besalduch J; Jarque I; Salama P; Rivas JA; Navarro B; Bladé J; Miguel JF;
Br J Haematol; 2001 Dec; 115(3):575-82. PubMed ID: 11736938
[TBL] [Abstract][Full Text] [Related]
9. Waldenström's macroglobulinemia. Report of a case with pulmonary involvement and improvement in pulmonary symptoms only following chlorambucil therapy.
Rabiner SF; Aprill SN; Radner DB
Am J Med; 1972 Nov; 53(5):685-9. PubMed ID: 4628013
[No Abstract] [Full Text] [Related]
10. Treatment options in Waldenström's macroglobulinaemia: the role of the purine analogues.
Owen RG
Expert Opin Pharmacother; 2001 Jun; 2(6):945-52. PubMed ID: 11585010
[TBL] [Abstract][Full Text] [Related]
11. IFN-alpha as induction and maintenance treatment of patients newly diagnosed with Waldenström's macroglobulinemia.
Vela-Ojeda J; García-Ruiz Esparza MA; Padilla-González Y; Rosas-Cabral A; García-Chávez J; Xolotl-Castillo M; Salazar-Exaire D; Arenas-Osuna J; Aviña-Zubieta JA; Vadillo-Buenfil M; Abraham-Majluf S
J Interferon Cytokine Res; 2002 Oct; 22(10):1013-6. PubMed ID: 12433280
[TBL] [Abstract][Full Text] [Related]
12. Waldenstrom's macroglobulinemia: a retrospective analysis of 40 patients from 1972 to 2001.
Ngan S; Rohatiner AZ; Matthews J; Williams A; Amess JA; Norton A; Lister TA
Semin Oncol; 2003 Apr; 30(2):236-8. PubMed ID: 12720143
[TBL] [Abstract][Full Text] [Related]
13. [Association of sarcoidosis and Waldenström's macroglobulinemia].
Collet E; Boulitrop-Morvan C; Dalac S; Camus P; Lambert D
Ann Dermatol Venereol; 1992; 119(12):971-4. PubMed ID: 1304690
[TBL] [Abstract][Full Text] [Related]
14. Therapy of macroglobulinaemia. Comparison of the effect of therapy on the level of monoclonal immunoglobulins and on clinical symptoms in four cases of waldenström's macroglobulinaemia and one case of IgA myeloma.
Pronk EA; Elkerbout F; Klein F; Radema H; Cleton FJ
Acta Med Scand; 1969 Oct; 186(4):273-81. PubMed ID: 4190857
[No Abstract] [Full Text] [Related]
15. Myelodysplastic syndrome with complex karyotypic abnormality in a patient with Waldenström's macroglobulinemia after sequential treatment with chlorambucil and fludarabine.
Shin SJ; Chun SH; Kim KO; Kim MK; Lee KH; Hyun MS; Cho HS
Jpn J Clin Oncol; 2005 Oct; 35(10):622-5. PubMed ID: 16172172
[TBL] [Abstract][Full Text] [Related]
16. Waldenström's macroglobulinemia.
Gertz MA; Fonseca R; Rajkumar SV
Oncologist; 2000; 5(1):63-7. PubMed ID: 10706651
[TBL] [Abstract][Full Text] [Related]
17. Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review.
Buske C; Sadullah S; Kastritis E; Tedeschi A; García-Sanz R; Bolkun L; Leleu X; Willenbacher W; Hájek R; Minnema MC; Cheng M; Bilotti E; Graef T; Dimopoulos MA;
Lancet Haematol; 2018 Jul; 5(7):e299-e309. PubMed ID: 29958569
[TBL] [Abstract][Full Text] [Related]
18. Pulmonary paraprotein production in Waldenström's macroglobulinaemia.
Hull RG; Barton EJ
Postgrad Med J; 1982 Jan; 58(675):57-8. PubMed ID: 6806789
[TBL] [Abstract][Full Text] [Related]
19. Polyneuropathy in Waldenström's macroglobulinaemia: reduction of endoneurial IgM-deposits after treatment with chlorambucil and plasmapheresis.
Meier C; Roberts K; Steck A; Hess C; Miloni E; Tschopp L
Acta Neuropathol; 1984; 64(4):297-307. PubMed ID: 6095580
[TBL] [Abstract][Full Text] [Related]
20. Waldenström's macroglobulinaemia.
Johnson SA; Oscier DG; Leblond V
Blood Rev; 2002 Sep; 16(3):175-84. PubMed ID: 12163003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
